key: cord-1010626-82jxhuk0 authors: Clancy, Cornelius J; Nguyen, M Hong title: Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020 date: 2020-09-30 journal: Open Forum Infect Dis DOI: 10.1093/ofid/ofaa464 sha: d377df9e9dd2bd71ce98f27d9ff590a105a71ab6 doc_id: 1010626 cord_uid: 82jxhuk0 Antimicrobial resistance is a pressing global threat, but companies developing antibiotics are failing. Large pharmaceutical companies recently created the AMR Action Fund, which will invest $1 billion in small antibiotic development companies. To understand the state of antibiotic development in the United States, we conducted a case study of new agents against carbapenem-resistant Gram-negative bacteria. Factors contributing to market failures were slow clinical uptake of drugs despite their effectiveness and safety, relatively small numbers of target infections that are insufficient to support existing drugs economically, and an excess of recently approved and pipeline agents with redundant spectra of activity. The AMR Action Fund will provide an immediate lifeline to companies in danger of failing due to an inability to secure investment, but it will not address issues identified in the case study or fix the antibiotic development model or marketplace. The Fund buys time for reforms to salvage antibiotic development. Antimicrobial resistant (AMR) infections cause ~700 000 deaths annually worldwide, a toll projected to reach 10 million by 2050 [1] . Despite the burden of AMR, the antimicrobial pipeline is under duress. One third of companies behind antibiotics approved by the US Food and Drug Administration (FDA) over the past decade have failed [2] . Large pharmaceutical companies, having abandoned the field for more lucrative products, are currently responsible for only 3 antibiotics in clinical trials [3] . Therefore, it is notable that over 20 of the world's biggest pharmaceutical companies launched the AMR Action Fund in July 2020. The Fund will invest $1 billion in small antibiotic development companies with the goal of bringing 2-4 agents to clinic by 2030 [4, 5] . It will also provide expertise and technical support and develop public-private alliances that champion sustainable antibiotic development. Fixing the broken development model is crucial to solving the looming AMR crisis [4] . In this Perspective, we review the state of antibiotic development in the United States. In addition, we offer views on the AMR Action Fund and potential pipeline and marketplace reforms. The dire condition of the antibiotic pipeline drew widespread attention in the early aughts, leading to governmental and public-private financial "push" incentives for drug development [6, 7] . The number of investigational antibiotics in clinical trials increased from 13 in 2001 to the mid-30s by 2008-2009 [3] . The FDA has approved 15 new antibiotics since 2014. In 2019, however, US sales of all branded antimicrobials were only ~$750 million, a paltry sum compared with revenue in other spaces (Table 1 ) [8] . In making investment decisions, companies determine a product's net present value (NPV), defined as projected earnings minus expected production costs (both expressed in present-day dollars). The industry standard NPV to invest in a new drug is ~$200 million. The NPV of the average neurologic or musculoskeletal agent is $720 million-$1.15 billion, whereas that of the average antibiotic is minus $50 million [9] . After the flight of big pharmaceutical companies, antibiotic development is dominated by small companies. Twenty-five antibiotics were in trials in December 2019, the lowest total in 11 years [3] . New antibiotics against carbapenemresistant (CR) Gram-negative bacteria are a useful case study of the moribund market. Pathogens such as CR Enterobacteriaceae (CRE), CR Pseudomonas, and CR Acinetobacter have been designated as urgent drug development priorities for 2 decades [11, 12] . Carbapenem-resistant infections are associated with particularly poor outcomes, and polymyxins (colistin, polymyxin B), previous frontline treatments, are suboptimal and toxic. The FDA has approved 7 antibiotics with anti-CR Gram-negative activity since 2014; 8 other agents are in trials [3, 13] . Antibacterials carry significant built-in market disadvantages compared with other drugs, including stewardship mandates to limit inappropriate use, relatively short treatment courses, and effectiveness of cheap older agents against most infections. Three particular factors have also contributed to economic failure of new anti-CR Gram-negative agents. First, clinical uptake of drugs has been steady, but slow, despite their effectiveness and safety. Using US prescription data, we estimated that new antibiotic use against CRE infections did not exceed that of intravenous polymyxins until December 2018 [14] . Strich et al [15] subsequently used a US hospital billing database to estimate that prescriptions of ceftazidime-avibactam, the most widely used new anti-CRE agent, approached, but did not equal, those of colistin in the fourth quarter of 2017 (excluding cystic fibrosis patients). Factors constraining use may include cost, limited clinical trial data against CR infections, unavailability of commercialized susceptibility testing, holes in spectra of activity (eg, metallo-β-lactamases, pandrug-resistant Acinetobacter), and concerns about emergence of drug resistance [14, 15] . A second factor is that CR infections remain rare in the United States [16] . Carbapenem-resistant Enterobacteriaceae and CR Acinetobacter were estimated to cause ~13 000 and ~8500 infections, respectively, in US hospitals in 2017; ~32 500 multidrugresistant (but not necessarily CR) Pseudomonas infections were identified [17] . Domestic sales of new anti-CRE Many innovative products are already in earlystage pipeline, including drugs and therapeutic approaches that differ from traditional antibiotics. No guarantee for returns on investment given costs, uncertainty, and time-intensive nature of drug development. Superiority trials for treating infections are complex, difficult to enroll, costly and often yield unpredictable and difficult to interpret outcomes [21] . drugs (each of which was also active against CR Pseudomonas) in 2018 were $101 million [16] . Based on positioning of agents at US hospitals, we calculated a potential market of $169 million-$439 million annually. Strich et al [18] used patient-level microbiology and pharmacy data from 134 US hospitals to estimate needs of 39-138.2 days of therapy (DOT) per 10 000 encounters for novel antibiotics against Gram-negative bacteria with difficult-to-treat resistance, including CRE, CR Pseudomonas, and CR Acinetobacter. Extrapolating from these data, treatment opportunities for such antibiotics are ~11 300-400 000 DOT/ year. Taking 2018 ceftazidime-avibactam pricing (average wholesale: $1076/day) as a benchmark [16] , the corresponding market size is $120 million-$430 million. At prices of $500/day, the expected annual US market shrinks to ~$56 million-$200 million. Antibiotic development costs often exceed $1 billion; postapproval costs of regulatory compliance, manufacturing, distribution, etc are at least $350 million over 10 years [2] . Therefore, the market cannot support all currently approved antibiotics against CR Gram-negative bacteria, let alone pipeline agents, even if polymyxins were fully displaced [2, 16] . Finally, antibiotic development suffers from lack of innovation. Most anti-CR Gram-negative agents in the clinic or pipeline are derivatives of well established classes that are directed predominantly against CRE, at least partially redundant in spectra with existing antibiotics, and vulnerable to cross-resistance [13] . Likewise, numerous investigational agents are directed against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile, targets for which newly approved agents have had difficulty establishing themselves (Table 1) . Innovation is notable in the preclinical pipeline [19] , but products are far from clinic, and they will face similar economic pressures without changes in epidemiology or the marketplace. The AMR Action Fund will function as a push incentive for Phase 2-3 antibiotics, and it offers an immediate lifeline to companies in danger of failing due to an inability to raise money from investors [4] . The Fund embraces the "pay to play" concept that large pharmaceutical companies not developing antimicrobials should pay to support such efforts [1, 20] . Sponsoring companies are acknowledging the unique medical and societal value of antibiotics, and that many of their successful products depend upon preventing and treating infections. Other strengths are the number and experience of sponsors, potential for leveraging resources and expertise, outreach to public and private partners, and global focus. Challenges will be to identify and advance products against the most pressing clinical needs, limit pipeline redundancies, and foster innovation. A pipeline imbalanced toward derivative agents against pathogens such as non-metalloβ-lactamase-producing CRE or MRSA is inefficient and assures further product failures. The Fund's major weaknesses are that it does not directly address the 3 issues identified in our case study, nor will it fix the broken marketplace. Its most important charge will be to buy time to convince governments to enact reimbursement reforms ("pull" incentives) or implement new antibiotic development models. Descriptions, strengths, and weaknesses of proposals toward these ends appear in Table 2 . Most proposed pull incentives delink reimbursement from numbers of prescriptions. The United Kingdom and Sweden have enacted pilot subscription models, in which governments pay companies a fee for assured access to prioritized antibiotics. The US Congress has considered a linked model of enhanced reimbursement for use of new antibiotics against AMR pathogens at hospitals with stewardship programs (DISARM Act) and a delinked model that most closely resembles a subscription model (PASTEUR Act) ( Table 2 ) [20] . The fate of legislation is uncertain. A recent article called for greater up-front government investment in early-stage discovery and development rather than focusing on private sector profitability, with the goal of producing more innovative products that demonstrate clear superiority to existing antibiotics [22] . Another proposal for a noncommercial model bypasses the private sector by funding nonprofit organizations to develop antibiotics [23] . Nonprofit research and development Nonprofit entity(ies) would discover and develop agents against high-priority pathogens, modeled after programs for TB and malaria. Removes pressure to maximize return to investors or profit. Can complement, rather than replace for-profit model. No more likely than for-profits to successfully develop agents or pick winners. Concerns about numbers of new agents and innovation if for-profit companies are displaced. Antibiotic model must address multiple pathogens, unlike TB or malaria models. Even without profit imperative, entities still need to generate some revenue and face substantial fixed pre-and postapproval costs. The AMR Action Fund affords a window of opportunity to salvage antibiotic development. If these efforts fail, we risk returning to the dark days of 20 years ago. The task then will be more difficult and costly, even as AMR increases globally. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final report and recommendations. AMR Review website. 2016. Available at: https://amr-review. org/#:~:text=%E2%80%9CThe%20Review%20 on%20Antimicrobial%20Resistance,actions%20 to%20tackle%20it%20internationally. Accessed 23 Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia. AMR Solutions blog An analysis of antibacterial drug development trends in the US AMR action fund: a $1B down payment from industry. AMR Solutions blog AMR action fund. AMR action fund website Trends in antimicrobial drug development: implications for the future Infectious Diseases Society of America. The 10 × '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 Antibiotic and Antifungal Update Available at: www.ohe.org/publications/newdrugstackle-antimicrobial-resistance-analysis-eupolicy-options The top 20 drugs by 2018 U.S. sales. Available at Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis Critical analysis of antibacterial agents in clinical development Estimating the treatment of carbapenem-resistant Enterobaceriaceae infections in the United States using antibiotic prescription data Pharmacoepidemiology of ceftazidime-avibactam use: a retrospective cohort anlaysis of 210 US hospitals Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae Multidrug-resistant bacterial infections in U.S. hospitalized patients Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study The global preclinical antibacterial pipeline Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect? Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance The wrong cure: financial incentives for unimpressive new antibiotics Sustainable discovery and development of antibiotics-is a nonprofit approach the future?